Clinical Trial Details
| Trial ID: | L5186 |
| Source ID: | NCT00366379 |
| Associated Drug: | Gk Activator (2) |
| Title: | A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes. |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus Type 2 |
| Interventions: | DRUG: GK Activator (2) |
| Outcome Measures: | Primary: Percentage of patients at each dose who achieve FPG <100mg/dL., Throughout study | Secondary: Mean change in HbA1c and FPG from baseline to endpoint; absolute/relative changes in lipid profile., At intervals throughout study|AEs, laboratory parameters., Throughout study |
| Sponsor/Collaborators: | Sponsor: Hoffmann-La Roche |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 127 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2006-07 |
| Completion Date: | 2007-06 |
| Results First Posted: | |
| Last Update Posted: | 2016-11-02 |
| Locations: | Chandler, Arizona, 85225, United States|Oviedo, Florida, 32765, United States|Nampa, Idaho, 83687, United States|Evansville, Indiana, 47714, United States|Butte, Montana, 59701, United States|Canton, Ohio, 44718, United States|Portland, Oregon, 97239, United States|Greer, South Carolina, 29651, United States|Midland, Texas, 79707, United States|Richmond, Virginia, 23249, United States|Tallinn, 10138, Estonia|Tartu, 50406, Estonia|Tartu, 50708, Estonia|Tartu, 51014, Estonia|Jelgava, 3001, Latvia|Riga, 1002, Latvia|Riga, 1038, Latvia|Chihuahua, 31238, Mexico|Guadalajara, 44340, Mexico|Guadalajara, 44650, Mexico|Pachuca, 42086, Mexico |
| URL: | https://clinicaltrials.gov/show/NCT00366379 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|